Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

4
Tanduay aims to enter Europe within 3-5 years

2018-06-17 bworldonline
TANDUAY DISTILLERS, Inc. (TDI) looks to enter the European market within the next three to five years, as it scouts for opportunities to bring its rum brand overseas.
PNB LTG

7
Tanduay overtakes Bacardi as world’s best-selling rum brand

2018-06-13 bworldonline
SALES of Tanduay rum in Visayas and Mindanao fueled Tanduay Distillers, Inc. (TDI)’s performance in 2017, allowing it to overtake international brand Bacardi in a world ranking of top-selling rum brands by think tank Drinks International.
PSKXF PHSXY PSE LTG

7
LT Group#39;s Nabha Power shuts 700 MW unit due to coal shortage

2018-06-07 moneycontrol
L&T Group firm Nabha Power Ltd (NPL) said that it has been forced to shut a 700 megawatts (MW) unit of Rajpura thermal power station due to shortage of coal.
CLNDY 533278 COALINDIA LTG

36
Stock price index up slightly in thin trade

2018-06-06 business.inquirer.net
The benchmark Philippine Stock Exchange index (PSEi) managed to close with a small gain on Wednesday, a day after inflation fears eased with the release of data for May.
GTCAP GTCXY GTMEY BDOUY BDOUF JBFCF PHSXY GTMEF PSE SPHXF SPHZF GLOPA AYAAF PSKXF AYAAY JBFCY GLOPP SMPH BDO GLO SPHXY JFC BBRRF BLOOM ALI LTG

50
BusinessWorld Economic Forum 2018 tackles realities of disruption

2018-05-31 bworldonline
Last May 18, BusinessWorld, the most read and most respected business newspaper in the Philippines, triumphantly staged the third edition of its annual BusinessWorld Economic Forum in the Grand Ballroom of Grand Hyatt Manila, in Bonifacio Global City, Taguig City.
MER GTCAP GTCXY SVTMF SMCP1 ABZPY BDOUY SM BDOUF SMGBF SMIVY SMC PNX3B PNXP PNX3A MPCFF PNX UBNC MPCIY SMGBY ABZPF BDO SMC2B SMC2A SMC2D SMC2C MPI SMC2F SMC2E AP LTG

12
Stock index rallies to 7,800

2018-05-15 business.inquirer.net
The local stock barometer rallied to the 7,800 level on Tuesday, perked up by the latest rebalancing of the closely tracked MSCI indices.
SMIVY PSKXF SVTMF LPZ PHSXY SM PSE LTG

51
Conglomerates deliver mixed Q1 results, but outlook remains positive

2018-05-15 bworldonline
CONGLOMERATES are expected to register better financial results this year, as the country’s top firms proceed with expansion programs amid a new tax regime and challenges in their respective businesses.
JGSMY GTCAP GTCXY SVTMF SMCP1 JGS SM AEV SMGBF SMIVY SMC ALGGY MPCFF PHSXY PSE AGI JGSHF DMC PSKXF MPCIY LPZ DMCIF SMGBY DMCP SMC2B SMC2A SMC2D SMC2C ABTZY MPI SMC2F SMC2E ALGGF DMCHY LTG

9
Tabacco, banking boost LT Group’s Q1 profits

2018-05-11 bworldonline
THE attributable profit of the LT Group, Inc. (LTG) jumped by 61% in the first quarter of 2018, boosted by its tobacco and banking units.
PSKXF PNB PHSXY PSE LTG

2
Tobacco, banking units lift LT Group Q1 bottom line

2018-05-11 bworldonline
LT Group, Inc. (LTG)’s attributable profit jumped by 61% in the first quarter of 2018, boosted by its tobacco and banking units.
LTG

4
Illicit cigarette trading still a concern, says Tan

2018-05-08 business.inquirer.net
After the fall of Mighty Corp. as a result of the government’s crackdown on illicit cigarette trading last year, some remnants of “underground” cigarette business continue to operate locally—at a smaller scale than before but still enough to cause concern, the chief of conglomerate LT Group Inc. (LTG) said.
PNB LTG

9
LT Group sets aside up to P11B for capex this year

2018-05-08 bworldonline
LT GROUP, Inc. (LTG) plans to spend P10-11 billion for capital expenditures in 2018, the bulk of which will be allocated for its property unit in a bid to expand its recurring income.
PNB AYAAY ALI LTG AYAAF

2
LT Group sets around P11 billion capex for 2018

2018-05-08 bworldonline
LT Group, Inc. (LTG) plans to spend P10 billion to P11 billion for capital expenditures in 2018, amid expectations of a better year given the government’s move to address illicit activities in tobacco trade.
LTG

45
Pure Foods share sale seen to become bigger

2018-04-10 business.inquirer.net
What is set to become the largest share sale in Philippine history may become even bigger after San Miguel Corp.’s chief said he could offer as much as a third of the conglomerate’s soon-to-be-consolidated food and beverage businesses to the investing public.
SMCP1 BDOUY MS.PRE PFP2 MS.PRF MS.PRG MS.PRA BDOUF SMGBF SMC MS GSMI SMPFF PFP PF SMPFY SMGBY BDO SMC2B SMC2A SMC2D MS.PRI SMC2C SMC2F MS.PRK SMC2E LTG

12
Stocks down as US-China trade war looms

2018-04-04 business.inquirer.net
The local stock barometer slipped below the 8,000-mark on Thursday as the brewing US-China trade war spooked regional markets.
SMIVY PSKXF SVTMF PHSXY SM PSE LTG

30
PSE index stays above 8,000, defies regional slump

2018-04-03 business.inquirer.net
The local stock barometer stabilized above the 8,000 mark on Tuesday, defying the slump across most regional markets on selective buying of large-cap stocks.
SVTMF PSKXF GTMEY AYAAY SM GLOPP SECB GLO SMIVY SYBJF PHSXY GTMEF PSE GLOPA ALI AYAAF LTG

Related Articles

ADAP: Adaptimmune Therapeutics Analysis and Research Report

8h - Asif

Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

Silicon Investor Message Boards

This table lists all message boards related to PSE:LTG / LT Group, Inc. on message board site Silicon Investor.

Liteglow (LTGL) TLTG: Teltran International, Inc.
TLTG The future!